European Archives - Page 956 of 1020 - European Medical Journal

EMJ

Studies Confirm Regorafenib Benefit in Pre-Treated Metastatic Colorectal Cancer

BARCELONA-LUGANO, 3 July 2015 – The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated…

EMJ

Patients with Lowest BMI Have Shortest Survival in Pooled Analysis of Bevacizumab in Metastatic Colorectal Cancer

BARCELONA-LUGANO, 1 July 2015 – Patients with the lowest body mass index (BMI) had the shortest overall survival in an analysis of bevacizumab studies

EMJ

SENRI Trial Opens Window to Evaluate NK1 Antagonists for Emesis Prevention in Oxaliplatin Chemotherapy

BARCELONA-LUGANO, 1 July 2015 – The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin…

EMJ

Immune System Response Directed by ‘Gut Reaction’ to Illness

SIGNAL projection from cells in the infected guts of mice influences the programming of immune system cells to either repair or protect the body…

EMJ

New Blood Tests May Quickly Diagnose IBS

DIAGNOSIS of irritable bowel syndrome (IBS), the most common gastroenterological condition in the USA, can now be achieved with just two blood tests…

ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain…

Results of the phase 4 EXELS study of high-risk patients with essential thrombocythemia

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust…

Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses…

EMJ

Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…

EMJ

Phase 2 MMY2002 trial of daratumumab in myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca…